Skip to content
Text “Loti” to 833-962-6682 to join the Loti Labs VIP Group!
Loti Labs Resources Peptides

IGF-1 LR3 and IGF-1 DES: Structural and Binding Evidence

Both of these analogs are modified forms of IGF-1 that bind IGF-binding proteins less strongly than the native molecule does.

Both of these analogs are modified forms of IGF-1 that bind IGF-binding proteins less strongly than the native molecule does. They reach that outcome through different structural changes [2,4,5]. The role of those binding proteins helps explain why the changes matter in cell assays.

IGF-binding proteins, the IGFBPs, regulate access to IGF receptors. They can sequester IGFs away from the type I IGF receptor, but their actions are not uniformly inhibitory. Interactions with cell surfaces or extracellular matrix can also enhance IGF activity [1]. IGF-1 LR3 and IGF-1 DES illustrate two structural routes to reduced IGFBP association, not its complete elimination [2,4,5].

IGF-1 DES: removal of three N-terminal residues

The truncated analog is des(1-3)IGF-1, or des(1-3) insulin-like growth factor-I. It lacks the first three amino acids of IGF-1, the tripeptide Gly-Pro-Glu, leaving 67 residues rather than 70 [2,3].

This analog is not purely a laboratory construct. Ballard and colleagues’ review reports its isolation from bovine colostrum, human brain and porcine uterus, and suggests that it arises through cleavage of IGF-1 after translation [2]. The bovine colostrum finding is documented directly by Francis and colleagues. They purified the truncated form alongside IGF-1 and IGF-2 and determined the amino acid sequences of all three [3].

In rat L6 myoblasts, the truncated form was the most potent of the three at stimulating protein synthesis and suppressing protein degradation. The truncated form was also more potent than intact IGF-1 in the DNA-synthesis assay [3]. Across cultured cells, the Ballard review describes the potency gain over IGF-1 as generally about tenfold [2]. This is not a fixed multiplier for every assay.

Why the higher potency? It follows from what the missing tripeptide removes. The absence of glutamate at position 3 contributes to much weaker binding to IGFBPs, leaving more of the analog available to engage the receptor [2]. The potency gain is therefore attributed mainly to reduced sequestration by binding proteins, rather than a universal increase in receptor affinity. Its size depends on the binding-protein context [2,4].

IGF-1 LR3: N-terminal extension and a residue substitution

LR3 lowers IGFBP binding by a different route and combines two changes. In Long [Arg3]-IGF-1, glutamate at position 3 of the IGF-1 sequence is replaced by arginine. A 13-residue extension is added at the N-terminus, making an 83-residue analog. The numbering of Arg3 refers to the IGF-1 portion, not the third residue of the extended molecule [4].

Francis and colleagues described these molecules as recombinant fusion protein analogs. Their extension comprised the first 11 residues of methionyl porcine growth hormone followed by Val-Asn [4]. This structural definition distinguishes Long [Arg3]-IGF-1 from both the truncated DES analog and unmodified IGF-1.

The result ranks like this. Across the cell lines that released IGFBPs into their culture medium, Francis and colleagues found Long [Arg3]-IGF-1 and des(1-3)IGF-1 to be the most potent, followed by Long [Gly3]-IGF-1, then Long IGF-1, with unmodified IGF-1 the least potent [4]. Here, Long IGF-1 means IGF-1 carrying the 13-residue extension, and Long [Gly3]-IGF-1 means the same extended molecule with glycine in place of Glu3. DES and LR3 therefore fell in a similar top tier in those systems. The authors linked the enhanced activity to altered IGFBP interactions [4].

Species differences in IGFBP association

The extent to which these analogs associate with plasma binding proteins depends on the species. Lord and colleagues measured IGF-1, des(1-3)IGF-1 and LR3 IGF-1 association in rat, sheep, human, pig and chicken plasma. The variants showed extremely weak association in rat plasma, but appreciable binding in the other four species [5]. This was a binding study, not a direct comparison of biological potency across species.

Ligand blots nevertheless showed the same order of association in all five species: IGF-1 highest, des(1-3)IGF-1 intermediate and LR3 IGF-1 lowest [5]. Species-dependent binding is not evidence that this ranking reversed. The study also found only slight between-species differences with purified rat, sheep and human IGFBP-3, distinguishing the isolated protein from whole plasma [5].

The 1992 cell experiments address a different part of the comparison. In chicken embryo fibroblasts, which released no detectable IGFBPs into the medium, Long [Arg3]-IGF-1 was less potent than unmodified IGF-1 [4]. That observation concerns LR3 in that cell system; it does not establish that DES loses every potency advantage wherever IGFBPs are absent.

Side by side

Property IGF-1 DES IGF-1 LR3
Structural change N-terminal Gly-Pro-Glu removed; 67 residues [2,3] Glu3 replaced by Arg3 in the IGF-1 portion, plus a 13-residue N-terminal extension; 83 residues [4]
IGFBP association Reduced relative to IGF-1 [2,5] Reduced relative to IGF-1, with lower ligand-blot association than DES in the five species examined [5]
Reported origin Isolated from bovine colostrum in the primary study; other tissue sources are summarized in a review [2,3] Engineered recombinant fusion protein analog [4]
Potency in the IGFBP-secreting cell systems examined Similar top tier to LR3 [4] Similar top tier to DES [4]
Evidence from chicken embryo fibroblasts without detectable secreted IGFBPs No universal conclusion drawn here for DES Less potent than native IGF-1 in that system [4]

Interpreting the published comparisons

Three distinctions matter when reading these reports. First, plasma binding results are species dependent and are not potency measurements [5]. Second, the presence of secreted IGFBPs differs among cell systems, and this affects interpretation of the reported biological responses [4]. Third, DES and LR3 are structurally distinct molecules, not interchangeable names. Residue deletion, residue substitution and an N-terminal extension describe different changes [3,4].

These findings explain why a single potency claim cannot summarize both analogs across all conditions. They concern the molecules and experimental systems in the cited publications, not the identity, performance or suitability of a supplier’s material.

References

  1. Firth SM, Baxter RC. Endocr Rev. 2002;23(6):824-854. Review. DOI: 10.1210/er.2001-0033. PMID 12466191.
  2. Ballard FJ, et al. Int J Biochem Cell Biol. 1996;28(10):1085-1087. Review. DOI: 10.1016/1357-2725(96)00056-8. PMID 8930132.
  3. Francis GL, et al. Biochem J. 1988;251(1):95-103. DOI: 10.1042/bj2510095. PMID 3390164.
  4. Francis GL, et al. J Mol Endocrinol. 1992;8(3):213-223. DOI: 10.1677/jme.0.0080213. PMID 1378742.
  5. Lord AP, et al. J Endocrinol. 1994;140(3):475-482. DOI: 10.1677/joe.0.1400475. PMID 7514204.

This content is intended for research purposes only and is not meant to constitute medical advice. Not for human or veterinary use.

Research-use notice

This educational material discusses laboratory research concepts only. Loti Labs products are intended strictly for research and development use and are not for human consumption.

Ready to explore?

Browse high-purity research materials by format or view the full catalog.